Skip to main content
GeneOne Life Science, Inc. logo

GeneOne Life Science, Inc. — Investor Relations & Filings

Ticker · 011000 ISIN · KR7011000007 KO Professional, scientific and technical activities
Open in API
Filings indexed 490 across all filing types
Latest filing 2025-04-02 Director's Dealing
Country KR South Korea
Listing KO 011000

About GeneOne Life Science, Inc.

https://www.genels.com/en/

GeneOne Life Science, Inc. is a biopharmaceutical research and development company specializing in nucleic acid-based biomedicines. The company's core focus is on developing DNA and mRNA vaccines, particularly for emerging infectious diseases, leveraging its rapid development platforms. In therapeutics, GeneOne utilizes a proprietary DNA plasmid delivery technology to enable the expression of recombinant proteins and plasmid-encoded monoclonal antibodies (Plas-mAbs®). This non-viral vector approach is designed to offer a safer and more cost-effective alternative to traditional gene therapies and cell-line derived monoclonal antibody treatments for conditions such as cancers and autoimmune disorders. The company also develops immunomodulatory small molecule drugs. Through its subsidiary, GeneOne possesses cGMP-grade manufacturing capabilities for DNA plasmids, supporting its internal pipeline and contract manufacturing services.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Joel Neal Maslow) of GeneOne Life Science, Inc. This type of filing is a standard regulatory requirement for reporting insider shareholdings and transactions, which falls under the 'Director's Dealing' category.
2025-04-02 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders and Others' (최대주주등소유주식변동신고서) filed with the Korean regulatory authority (DART). It details specific changes in share ownership by company executives and major shareholders, including the name of the individual, the number of shares changed, and the reason for the change. This falls under the category of 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels.
2025-04-02 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides the official outcome of the shareholder meeting held on March 26, 2025. It details the voting results for various agenda items, including financial statements, director appointments, and auditor appointments, noting that several items failed to meet the quorum. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement.
2025-03-26 Korean
사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for GeneOne Life Science, covering the fiscal year from January 1, 2024, to December 31, 2024. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This constitutes a full annual financial report, which falls under the '10-K' category in the provided classification schema. FY 2024
2025-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) filed by GeneOne Life Science. It provides a summary of the audit opinion and key financial data (assets, liabilities, profit/loss) for the fiscal year ending 2024-12-31. While it contains financial data, it is a regulatory disclosure announcing the receipt and submission of the audit report to the exchange, rather than the full audit report document itself. According to the 'Menu vs Meal' rule, this is a report publication announcement. FY 2024
2025-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for the 49th Annual General Meeting of GeneLife Sciences. It contains the meeting agenda, details on voting procedures (including electronic voting), director/auditor candidate information, and management reference materials (business overview, board activities, etc.). This document is a formal notice sent to shareholders to provide information and request votes for the upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2025-03-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.